Page last updated: 2024-09-02

1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine and ag 538

1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine has been researched along with ag 538 in 1 studies

Compound Research Comparison

Studies
(1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine)
Trials
(1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine)
Recent Studies (post-2010)
(1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine)
Studies
(ag 538)
Trials
(ag 538)
Recent Studies (post-2010) (ag 538)
90230015

Protein Interaction Comparison

ProteinTaxonomy1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine (IC50)ag 538 (IC50)
integrase, partialHuman immunodeficiency virus 14.0628
lens epithelium-derived growth factor p75Homo sapiens (human)4.0628
alkaline phosphatase, intestinalHomo sapiens (human)3.545
alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproproteinHomo sapiens (human)9.49
intestinal alkaline phosphatase precursorMus musculus (house mouse)3.6945
alkaline phosphatase, germ cell type preproproteinHomo sapiens (human)5.59
Epidermal growth factor receptorHomo sapiens (human)2.3603
Insulin-like growth factor 1 receptorHomo sapiens (human)0.061
DNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)0.28
large T antigenBetapolyomavirus macacae0.82

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J1

Other Studies

1 other study(ies) available for 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine and ag 538

ArticleYear
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
    Nature chemical biology, 2009, Volume: 5, Issue:10

    Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection

2009